We invest in companies
that
change the world

The evolution of Ventures
Making the apparently impossible, possible, is the way progress has always been made. Our aim is to invest in ventures that facilitate and accelerate the progress for the benefits of all. With that in mind we have created Vikvest Ventures as an expert investment vehicle to make available to the right ventures that share our vision, our capital, experience and network. If you feel your venture can make a difference at scale, you should reach us to make it happen.
Our investment level is flexible and will depend on the reach of each project.
Our reach is international with presence in Switzerland, UK, Finland and USA.

We invest in
what comes
next

Discover our cases
From stories to IPO and more
We are one of the most leading venture capital new firms, with over $400 million in funds under management. But we do a lot more than invest, we work with companies to take them to the next level, closer to their future. We got years of experience, expertise, excecuting and acelerating global markets.
Biomind
The next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules.
Moolec
Food science company producing real animal proteins in plants to create affordable, animal-free ingredients for a more sustainable and equitable global food system.

Moolec Science, a Pioneer in Molecular Farming and Food Ingredient Technology, to List on Nasdaq at $500 Million Valuation Through Business Combination with LightJump Acquisition Corp.
Eternal
Technology driven alternative protein company producing nutrient-rich and sustainable foods accessible to everyone.
EvokAI
A MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector.

EvokAI Creative Labs announces plans to go public in 2022 at $70 Million valuation on Toronto Stock Venture Exchange.
 Charlotte’s Web
Industry leading, vertically integrated hemp business that produces high quality health supplements derived from phytocannabinoid extracts.
Novaphar
The new era of science applied to modern medicine. Novaphar innovates in the molecule to market lifecycle through a tailor-made process that provides a fast and competitive drug development, bridging the gap from innovation to patients.
Nutrecon
The protein revolution. Creating the meal of tomorrow to transform and energize your life. Nutrecon produces different kinds of foods more sustainably and efficiently by making them from plants and fungi, cultivating them directly from cells, or producing them by fermentation.
Voulu Ventures
An expert investment vehicle to support, accelerate and transform startups, small and mid-size ventures within the Finnish ecosystem in the shortest period of time. From Finland to the World.
CEO & Chairman of the Board

Alejandro Antalich

Mr. Antalich is the former Chief Executive Officer of the Canadian Company ICC Labs Inc. (TSXV), the first publicly traded company in the world to sell cannabis to a federal government, bridging the gap between the stigma behind certain controlled substances and regulators. Through strategic foresight, determination, commitment, responsibility, teamwork and passion, he led ICC Labs to its successful sale to Aurora (TSX) in November 2018, one of the largest participants in the industry, a $300 million transaction. An entrepreneur and investor with a commercial instinct and vision towards business growth, with expertise in public markets, mergers and acquisitions, corporate strategy, medtech and foodtech sectors, pharmaceutical industry, operations, manufacturing and product development. A savvy negotiator that manages unique relationship building skills. Focused on innovation, biotechnology, biomedical sciences and clinical research, he also leads Biomind Labs Inc., a Canadian publicly traded life sciences company specialized in fast acting psychedelics and tailored drug delivery systems targeting specific therapeutic indications. He sits on the boards of several companies.

Chief Investment Strategy Officer

Simon Vumbaca

Mr. Vumbaca has over 20 years of experience as a strategic advisor to senior leaders and influencers and has worked in the background globally throughout the corporate, financial and governmental worlds. He is deeply passionate about having a holistic birds-eye approach to every unique situation, considering all the angles. Simon's broad spectrum of clients includes Formula 1 racing tracks, Moto GP riders, athletes, pharmaceuticals, footballers, agents, high profile individuals and government officials. An expert in corporate strategy, public sector strategy, mergers & acquisitions, organizational strategy and functional strategy, with focus on turbo-boosting answers to the challenges companies face to ensure a successful outcome. He sits on the boards of several companies and can be available as a non-executive director. He works in English, Spanish, French, and Italian primarily.

Chief Business Officer

Tuula Palmén

Mrs. Palmén has 20 years of experience in Finnish innovation and industrial policy. She has participated in planning and execution of national and regional strategies focusing on life science, biotech, pharma, food, digital health, medtech and sustainability. She led the development of Finnish synthetic biology ecosystem and its integration to global ecosystems, and Health Capital Helsinki to create the basis for the Helsinki Metropolitan region to become one of the leading health hubs in Nordics and Europe. She was responsible for the development of the life science field in Oulu and in Helsinki. She received her Ph.D from the University of Helsinki in 2003. She also is eMBA from Hanken School of Economics & SSE in 2020. Further, Mrs. Palmén has over 10 years of experience in international business in sales and marketing, in medical device, diagnostic and biotech industry at KONE Corporation, Tamro Corporation and Immuno Diagnostics.